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INTRODUCTION:  Gastrointestinal  stromal  tumors  (GISTs)  of  the  alimentary  canal  are  malignant  tumors
with  <1%  of  cases  diagnosed  in  esophagus.  These  cases  require  special  consideration  given their  close
proximity  to vital  structures  and  propensity  to be highly  aggressive.  Management  of patients  with  GISTs
has  been  transformed  since  the introduction  of  tyrosine  kinase  inhibitors.  In this  report,  we present  an
unusual  case  of  GIST  with  spontaneous  esophageal  perforation.
PRESENTATION OF  CASE:  A 39-year-old  Caucasian  male  presented  to our  hospital  with  complaints  of  severe
chest  and  abdominal  pain.  A diagnostic  chest  radiograph  revealed  a moderate  right-sided  pleural  effusion.
Subsequently,  an  esophagram  demonstrated  a perforation  proximal  to  an  elongated  stricture  in  the  distal
esophagus.  A  left  thoracotomy  was  performed  whereby  a  large  mediastinal  mass  ﬁrmly  attached  to  the
esophagus  and  gastroesophageal  junction  was  encountered.  The  neoplasm  involved  proximal  one-third
of  the  stomach  and  perforated  into  the  right  hemithorax.  Histopathological  evaluation  of  the  tumor  led
to  a diagnosis  of GIST.
DISCUSSION: GISTs  of  the  gastroesophageal  junction  are  uncommon  and  may  rarely  present  with
esophageal  perforation.  The  standard  of  care  for  treating  GIST  at present  includes  tyrosine  kinase
inhibitors.  This pharmacologic  agent,  along  with  improved  surgical  techniques  and  understanding  of
molecular  markers  for accurate  diagnosis,  will assuredly  continue  to  improve  overall  survival  of  patients
with  GISTs.
CONCLUSION:  When  stricture  or achalasia  is detected  on  imaging,  GIST  should  be  considered  in the  differ-
ential  diagnosis  for  individual  patients.  Additionally,  chest  and  abdomen  CT scans  of  may  be  performed
to  conﬁrm  presence  of  a tumor  mass,  thereby  ruling  out  achalasia.
gical © 2013 Sur
. Introduction
Gastrointestinal stromal tumors (GISTs) are the most common
esenchymal tumors of the alimentary canal that account for
.1–3% of all gastrointestinal malignancies. Lesions can occur
nywhere along the gastrointestinal tract, with the majority
rising in the stomach (60%) and small intestine (30%). Primary
IST of the esophagus, however, is rare and constitutes less
han 1% of all tumors of its kind.1 GIST of the gastroesophageal
unction presenting with esophageal perforation has seldom been
escribed in the literature. We  report here an unusual presentation
f GIST with spontaneous esophageal perforation, followed by a
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Open access under CC BYAssociates Ltd. Published by Elsevier Ltd. 
discussion of the unique aspects of prognosis and surgical manage-
ment of esophageal GIST in comparison to lesions in other primary
anatomic sites.
2.  Case report
A  39-year-old male presented to our hospital with severe chest
and abdominal pain after a few months of progressive dyspnea and
odynophagia. Recently, he had complaints of emesis after meals
and eventually became intolerant of solids and liquids. Addition-
ally, the patient admitted to an approximately 100 lb weight loss
over the past few years. Upon arrival, he was hypotensive and
septic, with hemoglobin of 11.9 g/dL and white blood cell count of
Open access under CC BY-NC-ND license. 18.6 thou/cu mm.  After resuscitation and stabilization, a diagnostic
chest radiograph revealed a moderate right-sided pleural effusion
that was drained via tube thoracostomy with an output of 1200 mL
serosanguineous ﬂuid. A subsequent esophagram demonstrated
-NC-ND license. 
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Fig. 1. Malignant gastrointestinal tumor (GIST) of the esophagus, clinically ruptured,
gross  appearance. This gross photograph of the 19 cm tumor demonstrates the typi-
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 perforation proximal to an elongated stricture in the distal
sophagus.
Due to the chronic nature of his symptoms, we made the pre-
umptive diagnosis of achalasia with perforation from a possible
ood bolus proximally and a surgical intervention was  deemed nec-
ssary. Our operative plan was to perform a left thoracotomy and
f necessary, dissect the diaphragm to mobilize the stomach. A sur-
ical approach from the right chest was decided to be a less ideal
y the surgical team due to the difﬁculties of mobilizing the intra-
bdominal esophagus and upper stomach.
A left thoracotomy was performed on this patient, during which
 large mediastinal mass ﬁrmly attached to the esophagus and
astroesophageal junction was encountered. The visible portion
f the mass measured approximately 6 cm and extended down
hrough the diaphragmatic hiatus. During the initial exploration,
he esophagus was mobilized with the afﬁxed neoplasm. At this
oint, the surgical team observed the perforation of the tumor into
he patient’s right hemithorax. Subsequently, the diaphragm was
issected laterally to expose the intra-abdominal esophagus and
tomach. The tumor involved the proximal one-third of the stom-
ch. Since it was impossible to gain distal control of the mass,
 midline abdominal exploration was performed followed by a
roximal gastrectomy and distal esophagectomy with reconstruc-
ion via gastric pull-up and esphago-gastrostomy in the left chest.
he diaphragm was then closed around the gastric pull-up. The
bdomen and thoracotomy were closed, and chest tubes were
laced.
Pathologic analysis of the ﬁbrous neoplasm removed from
he patient measured 19 cm × 15 cm × 14 cm and weighed 1291 g
Fig. 1). Histopathological evaluation of the tumor was consistent
ith a mixed spindle and epitheloid cell GIST. There was necrosis
resent in approximately 10% of the tumor with a 6 cm break in
he pseudocapsule. The mitotic index was 11 per 50 high-power-
eld. The malignant cells exhibited dense cellularity and marked
typia with a pushing tumor border (Fig. 2). Immunohistochemical
tudies revealed tumor neoplastic cells that stained positive for KIT
CD117) and CD34, while smooth muscle actin and S-100 protein
ere negative (Fig. 3).
Postoperatively,  the patient initially had an uneventful recov-
ry with no evidence of leak from his anastomosis. He was then
tarted on a diet. Subsequently, he developed an empyema on post-
perative day 7 in the left chest requiring an operative decortication
rom which he recovered completely. The patient did have poor
verall ﬁtness for someone of his age. His hospital course was  pro-
onged with on overall length of stay of 15 days due to sepsis and
alnutrition.
When the patient had satisfactorily recovered from his hospi-
alization to tolerate medical treatment, his case was presented
t our multidisciplinary tumor conference. The recommendation
ig. 2. Malignant gastrointestinal tumor (GIST) of the esophagus, microscopic appearance
nd (C) spindled areas growth, and brisk (11/50 high power ﬁelds) mitotic activity with
esignated as malignant.cal ﬂeshy appearance of a GIST. There is an area of cystic degeneration and necrosis,
supporting  malignancy, which contributed to the clinical rupture of this tumor. The
external surface has been marked with blue ink to facilitate evaluation of the tumor.
was  made that he receives imatinib for an extended period of time,
which would be determined by the status of his overall health and
response to the medication.
3.  Discussion
Since 1992, there has been a considerable increase in the
reported incidence of gastrointestinal stromal tumors. This surge
in the number of diagnoses per year may be attributed to
greater awareness and improved histopatholologic detection of this
neoplasm.2 It is now believed that GISTs arise from pluripotential
mesenchymal stem cells programmed to differentiate into inter-
stitial cells of Cajal in the myenteric plexus.3 A gain-of-function
mutation in the juxtamembrane domain of the c-kit gene with
constitutive, ligand-independent activation of KIT receptor tyro-
sine kinase is thought to cause tumorgenesis. Autophosphorylation
of the receptor, most often KIT (CD117) or platelet-derived growth
factor receptor alpha (PDGFRA), leads to constitutive activation of
the receptor and tumor growth.4
The immunohistochemical proﬁle of GISTs is characteristic, with
nearly 95% of tumors staining positive for KIT (CD117). Often the
staining is strongly diffuse in the cell cytoplasm. Less commonly,
a membranous or perinuclear pattern is observed. The intensity of
KIT staining can be inconsistent. A proper titer of the KIT/CD117
antibody must be used in order to avoid over-staining that could
mislabel other neoplasms as GIST. Staining intensity, however, has
no predictive value of tumor response to treatment.5 KIT-positivity
can also be found in other tumors, including melanoma, angiosar-
coma and neuroblastoma, and therefore is not sufﬁcient to make
. The tumor demonstrated (A) overall dense cellularity, a mixture of (B) epithelioid
 about 10% necrosis (not illustrated), all of which contribute to this tumor being
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tig. 3. Malignant gastrointestinal tumor (GIST) of the esophagus, immunohistoch
gainst (A) CD117 (cKit) and (B) CD34, with lack of reactivity with antibodies agai
ather than leiomyosarcoma or malignant nerve sheath tumor.
 diagnosis of GIST.6 A more convincing diagnosis can be made
ith concordance of tumor morphology and immunophenotype.
dditional expressed markers in gastrointestinal tumors include
D34 antigen (70%), smooth muscle actin (30–40%), desmin (<5%)
nd S100 protein (∼5%). The immunophenotype varies according
o anatomic site. GIST of the esophagus, gastric region and rectum
re often CD34 positive.
For  the few GISTs that are KIT-negative, mutations of the
DGFRA gene can be helpful in ruling out other lesions of
esenchymal origin. Recent advances have resulted in the identi-
cation of DOG1, a calcium-dependent receptor activated chloride
hannel protein, which seems to be expressed in GIST regardless of
utation type.7,8 Although DOG1 testing is not recommended for
IT-positive lesions, this marker can be utilized in categorization of
uspected cases of GIST not conﬁrmed by KIT and PDGFRA testing.
Histopathological features of GISTs generally fall into one of
hree categories.9 Spindle cell morphology is seen in nearly 70%
f cases and shows cells arranged in short fascicles or whorls with
niform cytology, nuclei with ﬁne chromatin and inconspicuous
ucleoli. Approximately 20% of lesions are epithelioid type, marked
y a nested architecture and more nuclear atypia compared to the
pindle type. Combined phenotypes of the previous two morpholo-
ies are observed in about 10% of patients.9 The case presented in
his report comes under this rare category of mixed spindle and
pitheloid cell GIST.
Fletcher  et al. in 2002 outlined a classiﬁcation scheme to deﬁne
he relative risk for malignant behavior in GISTs.10 The authors pro-
osed stratiﬁcation of patients with GISTs into low-, intermediate-
nd high-risk groups based on tumor size and mitotic index.
lthough the grading system is predictive in a majority of cases,
mall lesions with low mitotic rates however have been reported
o metastasize or become locally aggressive in rare instances.11l staining. The tumor showed dense positive reactivity with antibodies directed
 smooth muscle actin (SMA) and (D)S100. These results support this being a GIST
GISTs can present clinically in a myriad of ways. Smaller lesions,
which can in the millimeter range, are usually asymptomatic and
diagnosed incidentally or found at autopsy. Masses can grow as
large as 35 cm,  with a median size at presentation of 5 cm.12
In comparison to other malignant tumors, GISTs generally do
not metastasize lymphatics and therefore lymphadenectomy is
typically not indicated.13 The propensity of a GIST to become
malignant depends on the primary anatomic site. Esophageal
GISTs are rather aggressive malignancies due to their malignant
potential, high recurrence, and mortality rates.14 Historically, a
majority of patients with esophageal GIST have a late diagnosis
and consequently are associated with worse outcomes.15 In an
epidemiological study analyzing SEER data, the relative ﬁve-year
survival after diagnosis of primary GIST of the esophagus compared
to overall GIST at any location was 17% versus 45% respectively.16
According to the National Comprehensive Cancer Network,
surgery should be the initial therapy for a primary GIST with no
metastasis located in an anatomic site with a tolerable morbidity
risk related to a surgical procedure. Bearing in mind the adjacent
vital structures, this risk is relatively high for esophageal GISTs, and
the preferred mode of resection is controversial in the literature.
Removal of the tumor can be attempted via simple enucleation
or esophagectomy. Indications for each modality remain unclear
with regard to tumor size. Although esophagectomy carries higher
risks of morbidity and mortality, certain experts in this ﬁeld argue
that excision of larger lesions without complete local resection
is ineffective.17Simple enucleation of larger tumors may  result in
greater positive microscopic margins and recurrence rates. Tumors
with large volumes (i.e. >10 cm)  which are in close proximity to
the gastroesophageal junction are especially difﬁcult to resect with
adequate margins.18 Still, the attainment of negative microscopic
margins has not been shown to consistently increase long-term
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urvival. Further investigation and multicenter data on surgical
trategies for esophageal GISTs are needed. The advent of tyro-
ine kinase inhibitors has changed the standard of care for GISTs
nd as a direct consequence, survival of patients with GISTs has
ncreased since the introduction of FDA approval of imatinib mesy-
ate in 2002.2 Imatinib mesylate is a potent and selective inhibitor
f a family of structurally related tyrosine kinases, including KIT,
CR-ABL and PDGFRA. Neo-adjuvant treatment with imatinib may
mprove resectability by down staging the tumor. Adjuvant ther-
py is recommended for large tumors, marginally resectable small
umors, and unresectable primary localized GISTs. Drug resistance
s not infrequent and serum level surveillance has not been shown
o impact management of patients who experience resistance. For
hese patients and those who cannot tolerate imatinib, the newer
ultikinase inhibitor sunitinib malate may  delay median time to
umor progression.19
After a comprehensive literature review, the current case report
ight be the ﬁrst reported case to describe resection of a GIST of the
astroesophageal junction that presented with pseudoachalasia
nd esophageal perforation. The authors hope that the summariza-
ion of their clinical experience with this intriguing case may  assist
ith the management of such rare malignant entities.
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